Pfizer has unveiled the final phase of its $21 million investment which it says will establish Adelaide as a global manufacturing hub for a medicine commonly used to treat complications in people with cancer.
The multi-million dollar upgrade to the Adelaide manufacturing facility is set to be completed in mid-2016, allowing for the production and export of a biologic medicine to a global market valued at $4.6 billion.
The Adelaide site will form part of Pfizer’s global network of manufacturing facilities that produce biologic and biosimilar medicines for use by patients across the world.
David Gallagher, Pfizer Australia chairman and managing director, who joined South Australian Minister for Health Industries Jack Snelling MP in Adelaide to make the announcement, says the company’s Adelaide site “will become the largest biologic medicine manufacturer of its type in Australia”.
“This investment will establish the facility as an innovative world-leading manufacturing site and further enhance the skills and capabilities of more than 100 South Australian workers,” he says.
“The upgraded facility is estimated to generate more than $380 million for the South Australian economy over the next seven years, an achievement that would not be possible without the support of the South Australian Government.”
Gallagher acknowledged the support received from Health Industries SA and reaffirmed Pfizer’s commitment to research, manufacture and distribute high-quality, lifesaving medicines in South Australia.
“As a leader in biopharmaceuticals, Pfizer is making high quality biologic and biosimilar medicines available to help solve unmet medical needs – here in South Australia, across Australia and throughout the world,” he says.
“Biologic medicines hold the key to overcoming a range of life-threatening diseases. We will continue to work with the medical profession and all levels of government to ensure patients receive timely and affordable access to these important therapies.”